Scott Fishman

Scott Fishman is a serial entrepreneur, investor, and market/technology analyst with over 30 years’ experience as a strategic advisor to the medical technology and pharmaceutical industries. He currently serves as CEO of Envisage (a division of Ethos LifeScience Advisors), which he founded to provide commercial guidance entrepreneurs, startups, and new product developers in the healthcare space. He is also an enthusiastic angel investor and sits on the Life Science Investment Advisory Committee for Ben Franklin Technology Partners, one of the nation's most successful technology-based economic development programs.

Actively involved in graduate education, Scott co-created and serves as program executive for the Commercialization Acceleration Program (CAP) at the Wharton School of the University of Pennsylvania. He also serves as a professor in marketing, management, negotiations, and strategic planning in the MBA program at Philadelphia University; co-teaches a commercialization course to bioengineering students at Drexel University; and lectures in translational therapeutics at the University of Pennsylvania Medical School. He earned his master’s degree in advertising from the University of Texas and bachelor’s degree in liberal arts from the University of Pennsylvania.

ARTICLES BY SCOTT FISHMAN

  • Scott Fishman, Envisage - Medtech Market Assessment
    4 Shortcomings Of Intellectual Property-Focused Investing
    3/18/2016

    Intellectual property (IP) is pretty foundational to qualifying many health care ventures as “investable.” In theory, this sounds like a good idea. But the unpredictability of patent enforcement, the expense of securing IP, and the X-factor of competition are among the reasons why IP isn't the "whole story" when it comes to launching a new product.

  • 3 Mistakes To Avoid When Forecasting The Market For Your Medical Device
    9/21/2015

    I both conduct and teach due diligence, and I see a lot of business plans from healthcare entrepreneurs. Among other things, I look for a cogent value proposition, an understanding of an unmet need, and a realistic calculation of the addressable market. 
  • Rethinking The Medtech Value Curve — Moving Beyond Feature- And Cost-Based Differentiation
    6/17/2015

    All product development ventures face the essential question of whether the opportunity is worth pursuing. Sometime in the distant past, before the hijacking of healthcare by the insurance industry — perhaps 15 or 20 years ago — the path from technology concept to medical device was a straightforward one. If you had an idea with clinical merit, and you were self-possessed and persistent enough, you probably could find a way to get your product to market.
More Articles by Scott Fishman